Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7491MR)

This product GTTS-WQ7491MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7491MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6309MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ602MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ11653MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ8765MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ11245MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ1910MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ13103MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1522MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW